It was further shown that the mutation and abnormal expression level of EPHA3 were correlated with lung cancer and gastric cancer, respectively, which confirmed that EPHA3 could be considered as a target in cancer therapy [12,13]. This evidence concerns the gene EPHA3 and lung cancer.